A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Further information

An interventional, randomised, double-blind, parallel group, placebo-controlled, multi-national clinical study period.
Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Further information
 

Long Term Extension Trial of Setmelanotide (RM-493) for Patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Further information
 

A Phase 2, Two-Stage (Open-Label Run-in Followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled Study of Setmelanotide in Patients with Specific Gene Variants in the Melanocortin-4 Receptor Pathway
Further information
 

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency
Further information
 

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin.
Further information

A Registry of Patients with Biallelic Pro-Opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), or Leptin Receptor (LEPR) Deficiency Obesity, or Bardet-Biedl Syndrome (BBS), Treated with Setmelanotide

Eine länderübergreifende, nicht-interventionelle prospektive Kohortenstudie mit Patienten, die im Rahmen der routinemäßigen klinischen Versorgung mit humanen Wachstumshormonen (hGH) behandelt werden

Anwendungsbeobachtung zur Therapie von Patienten mit pädiatrischen Indikationen wie Wachstumshormon-Mangel (GHD), Small for Gestational Age (SGA), Ullrich-Turner-Syndrom (UTS) und von präpubertären Patienten mit chronischer Nierenerkrankung (CRI) sowie Substitutionstherapie bei Erwachsenen mit ausgeprägtem Wachstumshormonmangel (AGHD) mit rh-GH (rekombinantes humanes Wachstumshormon) Saizen®

•    ECLip Register
•    iDSD und DSD Register
•    Register für PatientInnen mit Hypothyreose
•    Register für PatientInnen mit Adrenogenitales Syndrom (AGS)
•    Diabetes-Patienten-Verlaufsdokumentation (DPV)
•    Strukturiertes Vor- und Nachsorgeprogramm nach Bariatrischer Chirurgie
•    Register für Patienten mit extremer Adipositas
 

•    Diabetes and Social Jet Lag
•    BMBF – JA Studie
•    Ulmer Kinderstudie
 

Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for the Treatment of Obesity
and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo-
Controlled Trial
EU trial number: 2023-507655-30-00
 

A 52-week randomized, double-blind, placebo controlled, multi-center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist
monoclonal antibody, for preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy
 

Weight maintenance in adolescents with obesity; long-term treatment with semaglutide 2.4mg s.c. once-weekly.

Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia.

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy.

Medizinprodukte-Studie für Kinder mit Diabetes.